Newborn screening for cystic fibrosis in Wisconsin: Comparison of biochemical and molecular methods

Pediatrics

Volumn 99, Issue 6, 1997, Pages 819-824

  Gregg, Ronald G ^a   Simantel, Amy ^b   Farrell, Philip M ^b,e   Koscik, Rebecca ^b   Kosorok, Michael R ^b   Laxova, Anita ^b   Laessig, Ronald ^c   Hoffman, Gary ^c   Hassemer, David ^c   Mischler, Elaine H ^d   Splaingard, Mark ^d  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c WISCONSIN STATE LABORATORY OF HYGIENE   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

cystic fibrosis; DNA testing; immunoreactive trypsinogen; newborn screening; population incidence

Indexed keywords

CHLORIDE; TRANSMEMBRANE CONDUCTANCE REGULATOR; TRYPSINOGEN;

ALLELE; APGAR SCORE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DNA DETERMINATION; FAMILY HISTORY; HUMAN; LUNG INFECTION; MAJOR CLINICAL STUDY; MALABSORPTION; MALNUTRITION; MECONIUM ILEUS; NEGRO; NEWBORN; NEWBORN SCREENING; PREVALENCE; PRIORITY JOURNAL; SWEAT TEST; UNITED STATES;

APGAR SCORE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA; HUMANS; INFANT, NEWBORN; LABORATORY TECHNIQUES AND PROCEDURES; MASS SCREENING; MUTATION; PREDICTIVE VALUE OF TESTS; RADIOIMMUNOASSAY; SENSITIVITY AND SPECIFICITY; TRYPSINOGEN; WISCONSIN;

EID: 0030993169     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.99.6.819     Document Type: Article

References (34)

1. Farrell PM, Mischler EH. Newborn screening for cystic fibrosis. Adv Pediatr. 1992;39:31-64
2. Crossley JR, Elliott RB, Smith PA. Dried-blood spot screening for cystic fibrosis in the newborn. Lancet. 1979;i:472-474
3. Heeley AF, Heeley ME, King DN, Kuzemko JA, Walsh MP. Screening for cystic fibrosis by dried blood spot trypsin assay. Arch Dis Child. 1982;57:18-21
4. Wilcken B, Brown ARD, Urwin R, Brown DA. Cystic fibrosis screening by dried blood spot trypsin assay: results in 75,000 newborn infants. J Pediatr. 1983;102:383-387
5. Hammond KB, Abman SH, Sokol RJ, Accurso FJ. Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations. N Engl J Med. 1991;325:769-774
6. Orenstein DM, Boat TF, Stern RC, et al. The effect of early diagnosis and treatment in cystic fibrosis: a seven-year study of 16 siblings. Am J Dis Child. 1977;131:973-975
7. Wilcken B, Chalmers G. Reduced morbidity in patients with cystic fibrosis detected by neonatal screening. Lancet. 1985;ii:1319-1321
8. Dankert-Roelse JE, Meerman GJ, Martin A, ten Kate LP, Knol K. Survival and clinical outcome in patients with cystic fibrosis, with or without neonatal screening. J Pediatr. 1989;114:362-367
9. Kalman YM, Kerem E, Darvasi A, DeMarchi J, Kerem B. Difference in frequencies of the cystic fibrosis alleles deltaF508 and W1282X, between carriers and patients. J Hum Gen. 1994;2:77-82
10. Wilcken B, Wiley V, Sherry G, Bayliss U. Neonatal screening for cystic fibrosis: a comparison of two strategies for case detection in 1.2 million babies. J Pediatr. 1995;127:965-970
11. Rock MJ, Mischler EH, Farrell PM, et al. Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels. Pediatrics. 1990;85:1001-1007
12. Rock MJ, Mischler EH, Farrell PM, Bruns WT, Hassemer DJ, Laessig RH. Immunoreactive trypsinogen screening for cystic fibrosis: characterization of infants with false-positive screening test. Pediatr Pulmonol. 1989;6:42-48
13. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245:1073-1080
14. Gregg RG, Wilfond BS, Farrell PM, Laxova A, Hassemer D, Mischler EH. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols. Am J Hum Genet. 1993;52:616-626
15. Ranieri E, Lewis BD, Gerace RL, et al. Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience. Br Med J. 1994;308:1469-1472
16. Hassemer DJ, Laessig RH, Hoffman GL, Farrell PM. Laboratory quality control issues related to screening newborns for cystic fibrosis using immunoreactive trypsin. Pediatr Pulmonol. 1991;57:76-83
17. Cutting GR, Kasch LM, Rosenstein BJ, et al. A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein. Nature. 1990;346:366-369
18. Ferrie RM, Schwarz MJ, Robertson NH, et al. Development, multiplexing, and application of ARMS tests for common mutations in the CFTR gene. Am J Hum Genet. 1992;51:251-262
19. Richards B, Skoletsky J, Shuber AP, et al. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet. 1993;2:159-163
20. Boat T, Welsh M, Beaudet AL. Cystic fibrosis. In: Schriver CL, Beaudet AL, Sly WS, Valle D, eds. Metabolic Basis of Inherited Disease. New York, NY: McGraw Hill; 1989:2649-2680
21. Kosorok MR, Wei WH, Farrell PM. The incidence of cystic fibrosis. Stat Med. 1996;15:449-462
22. Allen DB, Farrell PM. Newborn screening: principles and practice. Adv Pediatr. 1996;43:231-270
23. Wilcken B. Newborn screening for cystic fibrosis: its evolution and a review of the current situation. Screening. 1993;2:43-62
24. Kulczycki LL, Schauf V. Cystic fibrosis in blacks in Washington, DC: incidence and characteristics. Am J Dis Child. 1974;127:64-67
25. Kazazian HH, Jr. Population variation of common cystic fibrosis mutations. The Cystic Fibrosis Genetic Analysis Consortium. Human Mutation. 1994;4:167-177
26. Blythe SA, Farrell PM. Advances in the diagnosis and management of cystic fibrosis. Clin Chem. 1984;17:277-283
27. Rosenstein BJ, Langbaum TS, Metz SJ. Cystic fibrosis: Diagnostic considerations. Johns Hopkins Med J. 1982;150:113-120
28. Mohon R, Wagener J, Abman S, Seltzer W, et al. Relationship of genotype to early pulmonary function in infants with cystic fibrosis identified through neonatal screening. J Pediatr. 1993;122:550-555
29. FitzSimmons S. The changing epidemiology of cystic fibrosis. Curr Prob Pediatr. 1994;24:171-179
30. Kraemer R, Hardon B, Rossi E. Classification at time of diagnosis and subsequent survival of children with cystic fibrosis. Helv Paediatr Acta. 1977;32:107-114
31. Shwachman H, Redmond A, Khaw KT. Studies in cystic fibrosis: Report of 130 patients diagnosed under 3 months of age over a 20-year period. Pediatrics. 1970;46:335-343
32. Task Force on Neonatal Screening of CF. Neonatal screening for cystic fibrosis: position paper. Pediatrics. 1994;72:741-745
33. Dhondt JL, Farriaux JP. What do immunoreactive trypsin assays measure. Screening. 1994;3:33-38
34. Farrell PM, Aronson RA, Hoffman GL, Laessig RH. Newborn screening for cystic fibrosis in Wisconsin: first application of population-based molecular genetics testing. Wis Med J. 1994;93:415-421